Gilead Issues $3B Senior Notes maturing 2028–2034

Gilead’s $3.0 billion senior note offering, with stated maturities from 2028 to 2034 and coupons between 4.25% and 4.90%, represents a material debt issuance for a company whose core revenues remain concentrated in product sales. On a recent reported basis (Q1 2025), Gilead’s product sales totaled $6,613 million and total revenues $6,667 million, with the U.S. accounting for roughly 70% of product sales. Revenue concentration and product mix are relevant context for fixed-income and equity investors assessing this issuance. HIV medicines remain the company’s largest product category (Biktarvy reported $3.15 billion in product sales in Q1 2025). Oncology product lines contributed about $757 million in Q1 2025. Intangible assets and R&D investments also factor into Gilead’s financial profile: sofosbuvir has a net carrying value of $2.3 billion (Dec 31, 2025) and amortization expense was $2.4 billion in 2025, while IPR&D balances include material items such as a $1.75 billion allocation for sacituzumab govitecan-hziy (Trodelvy) in NSCLC and $0.55 billion for bulevirtide. Investors should weigh the note issuance alongside Gilead’s strategic priorities. Management’s near-term focus includes advancing virology programs (lenacapavir for HIV PrEP, bulevirtide for HDV) and expanding oncology via CAR‑T and ADC programs (for example, Yescarta, Tecartus, and Trodelvy combos). The company’s commercial model continues to rely heavily on U.S. wholesalers (90%+ distribution share) and third‑party distributors internationally. Key risk considerations remain legal and regulatory: ongoing product liability litigation, potential settlements, clinical program setbacks and regulatory review outcomes (examples in recent years include a Trodelvy NSCLC program discontinuation and prior R&D impairments). Macroeconomic and reimbursement pressures, plus patent expiration and generic competition risks, also bear on Gilead’s cash flow outlook and credit metrics. The company disclosed past impairments and ongoing pipeline uncertainties, which are relevant when modeling leverage and interest coverage after this debt issuance.